Mexico Oncology Clinical Trials Market Report 2022 to 2030

Mexico Oncology Clinical Trials Market Analysis

$ 3999

Mexico's oncology clinical trials market is projected to grow from $189.8 Mn in 2022 to $296.8 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022-30. The market will be driven by the country's growing expertise and infrastructure, as well as its commitment to international collaboration. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Laboratorios Silanes.

ID: IN10MXCT006 CATEGORY: Clinical Trials GEOGRAPHY: Mexico AUTHOR: Vidhi Upadhyay

Buy Now

Mexico Oncology Clinical Trials Market Executive Summary

Mexico's oncology clinical trials Market is projected to grow from $189.8 Mn in 2022 to $296.8 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022-30. Mexico is Latin America's second-largest pharmaceutical market and is in the top 15 worldwide pharma markets. In addition, there are significant chances for pharmaceutical firms in Mexico. Almost 90% of Mexico's pharmaceutical manufacturing is for the domestic market. Mexico has executed an enormous number of Free Trade Agreements (with over 30 nations, including Canada, the United States, Japan, Israel, and others). Prostate, colorectal, testicular, lung, and stomach cancer are the most prevalent kinds of cancer among Mexican males. Breast, thyroid, cervical, uterine corpus, and colorectal cancer are the most common cancers among Mexican women.

Mexico is a regional leader in oncology clinical trials, with an increasing number of research focusing on cancer therapy and prevention. The nation has a huge patient population and a well-established healthcare system, which has aided in the expansion of clinical trials in the sector. The discovery of novel cancer medicines, especially immunotherapy and targeted therapies, is one of the primary areas of emphasis for oncology clinical trials in Mexico. There are also multiple current research on cancer screening and early diagnosis, as well as investigations on the underlying genetic and molecular causes of various forms of cancer. While there are both opportunities and challenges in the Mexican oncology clinical trials scenario, the country's growing expertise and infrastructure, as well as its commitment to international collaboration, indicate that it will continue to play a significant role in the global oncology trials landscape.

mexico oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

In Mexico, there are numerous important drivers of growth for cancer clinical trials. The country's vast patient population and reasonably well-established healthcare system, which offers a solid platform for clinical research, are two of the most crucial aspects. Moreover, Mexico has an expanding network of research institutes and clinical trial locations, which is assisting in the expansion of cancer clinical trials. In the domain, there is also a major emphasis on innovation and cooperation, with several research institutes and pharmaceutical firms collaborating to create novel cancer treatments and medications. Additionally, the country's clinical trial regulatory environment has greatly improved in recent years, making it simpler and more economical to conduct high-quality studies that match international standards.

Market Restraints

There are also various obstacles to the expansion of cancer clinical trials in Mexico. One significant difficulty is the scarcity of clinical trial financing, especially for smaller or independent research institutes. A lack of skilled staff, such as clinical trial coordinators, data managers, and regulatory professionals, may also make it difficult to run high-quality clinical trials that match international standards. Another restraint is overcoming cultural and language obstacles to clinical trial participation, especially among underprivileged populations. This necessitates a greater emphasis on community participation and education, as well as measures to promote diversity and inclusion in clinical trial design and recruitment.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis International AG
Roche Holding AG
Sanofi S.A.
AstraZeneca plc
Merck & Co., Inc.
Eli Lilly and Company
Bristol Myers Squibb Company
Laboratorios Silanes (MEX)
Grupo Ferrer (MEX)

Notable Insights

January 2023, The University of New Mexico Comprehensive Cancer Center will soon investigate the possibility of treating advanced prostate cancer using cutting-edge radioisotope technology known as 177 Lu-PSMA-617. The University of New Mexico Cancer Center will be one of just a few institutions in the nation to take part in a clinical study to extend the use of theranostic therapy to patients with prostate cancer.
February 2022, A new clinical study at The University of New Mexico Comprehensive Cancer Center may help individuals with unusual cancer mutations get individualized cancer treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.